Asthma control and lung function after step down from high dose ICS/LABA combination therapy

P. Paggiaro, N. Gabriele, N. Crimi, L. M. Fabbri, D. Olivieri, A. Rossi, A. Papi (Pisa, Parma, Catania, Modena, Verona, Ferrara, Italy)

Source: Annual Congress 2011 - Asthma management and response
Session: Asthma management and response
Session type: Thematic Poster Session
Number: 3967
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Paggiaro, N. Gabriele, N. Crimi, L. M. Fabbri, D. Olivieri, A. Rossi, A. Papi (Pisa, Parma, Catania, Modena, Verona, Ferrara, Italy). Asthma control and lung function after step down from high dose ICS/LABA combination therapy. Eur Respir J 2011; 38: Suppl. 55, 3967

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008



Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001

Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy
Source: Eur Respir J 2005; 26: Suppl. 49, 382s
Year: 2005

Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007


Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003

Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007


Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009

Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009


First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021


Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017


Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001



The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 49s
Year: 2003

Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009